정맥내 면역글로불린 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Intravenous Immunoglobulin Market size is expected to reach USD 24.92 Billion in 2034 from USD 12.90 Billion (2025) growing at a CAGR of 7.59% during 2026-2034.

The global intravenous immunoglobulin market has experienced substantial growth due to increasing demand for therapies that treat immune deficiencies and autoimmune diseases. Intravenous immunoglobulin is a blood-derived therapy used to strengthen the immune system and manage various medical conditions. Its effectiveness in treating disorders such as primary immunodeficiency and neurological diseases has contributed to widespread adoption.

Key drivers include rising prevalence of immune-related disorders and growing awareness of advanced treatment options. Healthcare providers increasingly rely on intravenous immunoglobulin therapy to manage complex conditions and improve patient outcomes. Additionally, advancements in plasma collection and purification technologies have helped expand production capacity and improve treatment availability.

Looking ahead, the intravenous immunoglobulin market is expected to grow as research into immune-related diseases continues to advance. Expanding healthcare infrastructure and improved diagnostic capabilities may increase treatment demand. Ongoing innovation in plasma-derived therapies and expanding clinical applications are likely to support the long-term development of this market.

MARKET SEGMENTATION

By Application

• Immunodeficiency diseases
• CIDP
• Hypogammaglobulinemia
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal motor neuropathy
• ITP
• Kawasaki disease
• Guillain-Barre syndrome
• Others

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Other

COMPANIES PROFILED

• Biotest AG, Baxter, Octapharma AG, LFB, Grifols SA, CSL, China Biologics Products Inc, Kedrion, BDI Pharma Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Immunodeficiency diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. CIDP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Hypogammaglobulinemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Congenital AIDS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Chronic Lymphocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Myasthenia Gravis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Multifocal motor neuropathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. ITP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Kawasaki disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.11. Guillain-Barre syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.12. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Specialty Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Application
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Application
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Application
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Application
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Application
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL INTRAVENOUS IMMUNOGLOBULIN INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Biotest AG
  • 8.2.2 Baxter
  • 8.2.3 Octapharma AG
  • 8.2.4 LFB
  • 8.2.5 Grifols SA
  • 8.2.6 CSL
  • 8.2.7 China Biologics Products Inc
  • 8.2.8 Kedrion
  • 8.2.9 BDI Pharma Inc